RT Journal Article
SR Electronic
T1 Antibody responses to BNT162b2 mRNA COVID-19 vaccine in 2,015 healthcare workers in a single tertiary referral hospital in Japan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.01.21258188
DO 10.1101/2021.06.01.21258188
A1 Kageyama, Takahiro
A1 Ikeda, Kei
A1 Tanaka, Shigeru
A1 Taniguchi, Toshibumi
A1 Igari, Hidetoshi
A1 Onouchi, Yoshihiro
A1 Kaneda, Atsushi
A1 Matsushita, Kazuyuki
A1 Hanaoka, Hideki
A1 Nakada, Taka-Aki
A1 Ohtori, Seiji
A1 Yoshino, Ichiro
A1 Matsubara, Hisahiro
A1 Nakayama, Toshinori
A1 Yokote, Koutaro
A1 Nakajima, Hiroshi
YR 2021
UL http://medrxiv.org/content/early/2021/06/04/2021.06.01.21258188.abstract
AB We measured antibody responses in 2,015 healthcare workers who were receiving 2 doses of BNT162b2 mRNA vaccine against SARS-CoV-2. The vast majority (99.9%) had either seroconversion or a substantial increase in antibody titer. A multivariate linear regression model identified predictive factors for antibody responses which may have clinical implications.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe study procedures for sample collection and those for analyses were approved by Chiba University Ethics Committee on February 24th, 2021 (No. HS202101-03) and April 21st, 2021 (No. HS202104-01), respectivelyFunding StatementThis study was supported by a donation to Chiba University Hospital and the Future Medicine Founds at Chiba University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study procedures for sample collection and those for analyses were approved by Chiba University Ethics Committee on February 24th, 2021 (No. HS202101-03) and April 21st, 2021 (No. HS202104-01), respectively.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be available after this manuscript is accepted by Scientific Journal.